NANALYSIS SCIENTI

Nanalysis Scientific reported Q2 revenue of 9.72 million CAD and EPS of $0.00, missing consensus estimates (expectation: 12.55 million CAD revenue, EPS $0.01). The stock plunged about 10% to $0.13 after the release. Operationally, adjusted EBITDA, gross margins and the net loss improved, while the company cut costs and realigned its business model more toward organic growth. Management expects a stronger second half, citing better sales activity and strategic measures (revamping the dealer network, direct sales, new products). » More on de.investing.com

Nanalysis Scientific reported revenue of CAD 10.68 million for Q4 2025, missing the CAD 12.1 million forecast by 11.74%, after which the shares fell 10.34% to CAD 0.13. Revenue declined 13% year on year, gross margins in product sales and security services decreased, adjusted EBITDA fell 33% and the normalized net loss amounted to CAD 729,000. Management cites problems in the scientific equipment segment, macroeconomic headwinds and supply‑chain challenges, but emphasizes capital strengthening, government funding, strategic partnerships and measures to stabilize margins. » More on de.investing.com

Nanalysis Scientific posted a consolidated revenue decline of 12% to CAD 9.3 million in the third quarter of 2025 and a net loss of CAD 1.5 million, with gross margin on product sales falling from 52% to 44%. Adjusted EBITDA dropped to negative CAD 2,000 compared with a profit a year earlier. Management is driving a restructuring focused on proprietary technologies, expanding the services business and forging strategic partnerships to improve margins and long-term growth. In the near term, macroeconomic pressure, supply-chain problems and the discontinuation of resale activities are weighing on revenues. » More on de.investing.com